Agios Pharmaceuticals Inc (AGIO)

66.63
NASDAQ : Health Care
Prev Close 66.63
Day Low/High 0.00 / 0.00
52 Wk Low/High 39.24 / 67.74
Avg Volume 497.10K
Exchange NASDAQ
Shares Outstanding 48.39M
Market Cap 3.19B
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

(Graphic: Business Wire)

(Graphic: Business Wire)

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that IDHIFA ® (enasidenib) was granted approval from the U.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Agios Pharmaceuticals Inc. - AGIO

Newman Ferrara LLP Announces Corporate Governance Investigation Of Agios Pharmaceuticals Inc. - AGIO

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc.

Updated Data From Phase 1 Trial Of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses And Duration Of Response In Patients With Relapsed Or Refractory AML And An IDH2 Mutation

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral...

Agios To Present Updated Clinical Data From PKR Activator AG-348 At EHA

Data from IDHIFA® (Enasidenib) Phase 1 Trial in IDH2m R/R AML to be Presented

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

Obamacare? Trumpcare? These stocks don't care.

These 4 Healthcare Charts Are Signaling Buys

These 4 Healthcare Charts Are Signaling Buys

Here's a rundown of four technical setups that are showing solid trading potential.

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Here's how to rake in the profits off some potential big breakouts.

FDA Accepts New Drug Application And Grants Priority Review For Enasidenib In Relapsed Or Refractory AML With An IDH2 Mutation

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.

TheStreet Quant Rating: D (Sell)